View : 94 Download: 0
Halofuginone and other febrifugine derivatives inhibit prolyl-tRNA synthetase
- Halofuginone and other febrifugine derivatives inhibit prolyl-tRNA synthetase
- Keller T.L.; Zocco D.; Sundrud M.S.; Hendrick M.; Edenius M.; Yum J.; Kim Y.-J.; Lee H.-K.; Cortese J.F.; Wirth D.F.; Dignam J.D.; Rao A.; Yeo C.-Y.; Mazitschek R.; Whitman M.
- Ewha Authors
- SCOPUS Author ID
- Issue Date
- Journal Title
- Nature Chemical Biology
- vol. 8, no. 3, pp. 311 - 317
- SCI; SCIE; SCOPUS
- Febrifugine, the bioactive constituent of one of the 50 fundamental herbs of traditional Chinese medicine, has been characterized for its therapeutic activity, though its molecular target has remained unknown. Febrifugine derivatives have been used to treat malaria, cancer, fibrosis and inflammatory disease. We recently demonstrated that halofuginone (HF), a widely studied derivative of febrifugine, inhibits the development of T H 17-driven autoimmunity in a mouse model of multiple sclerosis by activating the amino acid response (AAR) pathway. Here we show that HF binds glutamyl-prolyl-tRNA synthetase (EPRS), inhibiting prolyl-tRNA synthetase activity; this inhibition is reversed by the addition of exogenous proline or EPRS. We further show that inhibition of EPRS underlies the broad bioactivities of this family of natural product derivatives. This work both explains the molecular mechanism of a promising family of therapeutics and highlights the AAR pathway as an important drug target for promoting inflammatory resolution.
- Appears in Collections:
- 자연과학대학 > 생명과학전공 > Journal papers
- Files in This Item:
There are no files associated with this item.
- RIS (EndNote)
- XLS (Excel)
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.